Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.

ABSTRACT: Bladder cancer ranks as the 10th most common cancer type globally, and muscle-invasive disease accounts for approximately 25% of newly diagnosed bladder cancers. Despite definitive treatment, 50% of patients with muscle-invasive bladder cancer (MIBC) develop metastasis within 2 years, leading to death. Perioperative systemic therapy is generally recommended to control local relapse or distant metastasis after surgical resection for patients with MIBC. Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the current standard treatment to improve oncologic control and survival outcomes. Adjuvant chemotherapy is recommended for patients with pathological T3-4 or positive lymph nodes after radical cystectomy if no neoadjuvant chemotherapy was given. Nonetheless, periopera

SUBMITTER: Kim KH 

PROVIDER: S-EPMC10172053 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature